You are here

Article Text

Article menu
Download PDFPDF
Letters
Progression of lupus nephritis during treatment with mycophenolate mofetil
  1. K Ahmadi-Simab,
  2. P Lamprecht,
  3. W L Gross
  1. Department of Rheumatology, University Hospital of Schleswig-Holstein, Campus Luebeck, and Rheumaklinik Bad Bramstedt, Ratzeburger Allee 160, 23538 Luebeck, Germany
  1. Correspondence to:
    Dr K Ahmadi-Simab
    ahmadirheuma-zentrum.de; ahmadiik-h.de

https://doi.org/10.1136/ard.2003.016600

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Lupus nephritis (LN) determines the prognosis of systemic lupus erythematosus. The standard treatment for the proliferative forms (focal and diffuse proliferative LN, WHO classes III and IV) is intravenous pulse cyclophosphamide in combination with oral prednisone (Austin scheme).1,2 Recently mycophenolate mofetil (MMF) has been shown to be as effective as standard pulse cyclophosphamide for the induction of remission in proliferative LN (n = 21 in each treatment group). Side effects of MMF were fewer than with pulse cyclophosphamide.3 We …

    View Full Text